Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/WAC_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/WAC_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/WAC_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/WAC_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/WAC_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/WAC_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/WAC_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/WAC_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/WAC_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/WAC_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/WAC_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004593015 | Thyroid | ATC | negative regulation of mitotic cell cycle | 117/6293 | 235/18723 | 1.93e-07 | 3.05e-06 | 117 |
GO:004217733 | Thyroid | ATC | negative regulation of protein catabolic process | 68/6293 | 121/18723 | 2.66e-07 | 4.08e-06 | 68 |
GO:004484316 | Thyroid | ATC | cell cycle G1/S phase transition | 119/6293 | 241/18723 | 2.68e-07 | 4.10e-06 | 119 |
GO:004277016 | Thyroid | ATC | signal transduction in response to DNA damage | 90/6293 | 172/18723 | 3.01e-07 | 4.52e-06 | 90 |
GO:000008216 | Thyroid | ATC | G1/S transition of mitotic cell cycle | 107/6293 | 214/18723 | 4.83e-07 | 6.99e-06 | 107 |
GO:000709312 | Thyroid | ATC | mitotic cell cycle checkpoint | 69/6293 | 129/18723 | 2.52e-06 | 2.96e-05 | 69 |
GO:003243524 | Thyroid | ATC | negative regulation of proteasomal ubiquitin-dependent protein catabolic process | 25/6293 | 35/18723 | 5.36e-06 | 5.75e-05 | 25 |
GO:000007513 | Thyroid | ATC | cell cycle checkpoint | 84/6293 | 169/18723 | 1.05e-05 | 1.04e-04 | 84 |
GO:001094813 | Thyroid | ATC | negative regulation of cell cycle process | 134/6293 | 294/18723 | 1.19e-05 | 1.15e-04 | 134 |
GO:190198813 | Thyroid | ATC | negative regulation of cell cycle phase transition | 116/6293 | 249/18723 | 1.33e-05 | 1.27e-04 | 116 |
GO:190336333 | Thyroid | ATC | negative regulation of cellular protein catabolic process | 43/6293 | 75/18723 | 2.07e-05 | 1.85e-04 | 43 |
GO:001657416 | Thyroid | ATC | histone ubiquitination | 30/6293 | 47/18723 | 2.16e-05 | 1.92e-04 | 30 |
GO:001623912 | Thyroid | ATC | positive regulation of macroautophagy | 37/6293 | 63/18723 | 3.73e-05 | 3.05e-04 | 37 |
GO:190305133 | Thyroid | ATC | negative regulation of proteolysis involved in cellular protein catabolic process | 37/6293 | 64/18723 | 6.00e-05 | 4.60e-04 | 37 |
GO:190280615 | Thyroid | ATC | regulation of cell cycle G1/S phase transition | 79/6293 | 168/18723 | 2.04e-04 | 1.35e-03 | 79 |
GO:200004522 | Thyroid | ATC | regulation of G1/S transition of mitotic cell cycle | 68/6293 | 142/18723 | 2.86e-04 | 1.82e-03 | 68 |
GO:004586134 | Thyroid | ATC | negative regulation of proteolysis | 146/6293 | 351/18723 | 9.84e-04 | 5.22e-03 | 146 |
GO:000651314 | Thyroid | ATC | protein monoubiquitination | 35/6293 | 67/18723 | 1.26e-03 | 6.58e-03 | 35 |
GO:003192911 | Thyroid | ATC | TOR signaling | 59/6293 | 126/18723 | 1.39e-03 | 7.19e-03 | 59 |
GO:190179915 | Thyroid | ATC | negative regulation of proteasomal protein catabolic process | 27/6293 | 49/18723 | 1.58e-03 | 7.99e-03 | 27 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
WAC | SNV | Missense_Mutation | | c.306C>G | p.His102Gln | p.H102Q | Q9BTA9 | protein_coding | tolerated(0.13) | benign(0.063) | TCGA-A2-A3XT-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | PR |
WAC | SNV | Missense_Mutation | | c.1142N>C | p.Val381Ala | p.V381A | Q9BTA9 | protein_coding | deleterious(0.03) | possibly_damaging(0.503) | TCGA-A8-A06X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
WAC | SNV | Missense_Mutation | novel | c.1798N>A | p.Glu600Lys | p.E600K | Q9BTA9 | protein_coding | tolerated(0.09) | probably_damaging(0.972) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
WAC | SNV | Missense_Mutation | novel | c.16A>G | p.Arg6Gly | p.R6G | Q9BTA9 | protein_coding | deleterious(0.04) | benign(0) | TCGA-AQ-A7U7-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Targeted Molecular therapy | rituximab | CR |
WAC | SNV | Missense_Mutation | rs200723559 | c.1586N>G | p.Asn529Ser | p.N529S | Q9BTA9 | protein_coding | tolerated(0.13) | possibly_damaging(0.584) | TCGA-BH-A0E0-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD |
WAC | SNV | Missense_Mutation | rs750794271 | c.376N>C | p.Asp126His | p.D126H | Q9BTA9 | protein_coding | deleterious(0.01) | probably_damaging(0.995) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
WAC | SNV | Missense_Mutation | | c.1887N>C | p.Leu629Phe | p.L629F | Q9BTA9 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-E2-A10C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
WAC | SNV | Missense_Mutation | | c.1595C>A | p.Ser532Tyr | p.S532Y | Q9BTA9 | protein_coding | tolerated(1) | possibly_damaging(0.598) | TCGA-GM-A2D9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
WAC | insertion | Frame_Shift_Ins | novel | c.1537_1538insT | p.Arg513LeufsTer8 | p.R513Lfs*8 | Q9BTA9 | protein_coding | | | TCGA-A2-A0EO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
WAC | insertion | Frame_Shift_Ins | novel | c.1538_1539insAGGGAGAATTATTAATCATATCCCCTCACCCCACCAA | p.Ser514GlyfsTer19 | p.S514Gfs*19 | Q9BTA9 | protein_coding | | | TCGA-A2-A0EO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |